Investigational drug · Phase 2
RYZ711
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Prostate Cancer (Adenocarcinoma), Adenocarcinoma of the Prostate, Metastatic Castration-resistant Prostate Cancer (mCRPC).
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "RYZ711"
First trial start
2026
Oct 5, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RYZ711", any sponsor or status.
Conditions studied
As listed on its trial records.
- Prostate Cancer (Adenocarcinoma)
- Adenocarcinoma of the Prostate
- Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Biochemical Recurrence (BCR)
- High-Risk Localized Prostate Cancer
Approved drugs for the same conditions: Prostate cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "RYZ711" as an intervention, largest first.
- RYZ711 Diagnostic Platform StudyRecruiting
RayzeBio, Inc.Industry
NCT07862582 · 116 participants (planned) · Start Oct 5, 2026 · Primary completion Dec 2027
Drug: RYZ711 · For: Prostate Cancer (Adenocarcinoma); Adenocarcinoma of the Prostate; Metastatic Castration-resistant Prostate Cancer (mCRPC) and 3 more
Sites: Omaha, Nebraska
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Prostate Cancer (Adenocarcinoma)
- aglatimagene besadenovecCAN-2409, AdV-tkPhase 35 trials
Candel Therapeutics, Inc. · Prostate Cancer, Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)
- AS1986NSPhase 21 trial
Antelope Surgical Solutions, Inc · Prostate Cancer, Prostate Cancer (Adenocarcinoma), Fluorescence Imaging
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.